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Insulin-like peptide 3 (INSL3) is a hormone and/or paracrine factor which is a member of the
relaxin peptide family. It has key roles as a fertility regulator in both males and females.The
receptor for INSL3 is the leucine rich repeat (LRR) containing G-protein coupled receptor 8
(LGR8) which is now known as relaxin family peptide receptor 2 (RXFP2). Receptor activa-
tion by INSL3 involves binding to the LRRs in the large ectodomain of RXFP2 by residues
within the B-chain of INSL3 as well as an interaction with the transmembrane exoloops
of the receptor. Although the binding to the LRRs is well characterized the features of the
peptide and receptor involved in the exoloop interaction are currently unknown.This study
was designed to determine the key INSL3 determinants for RXFP2 activation. A chimeric
peptide approach was ﬁrst utilized to demonstrate that the A-chain is critical for receptor
activation.ReplacementoftheINSL3A-chainwiththatfromtherelatedpeptidesINSL5and
INSL6 resulted in complete loss of activity despite only minor changes in binding afﬁnity.
Subsequent replacement of speciﬁc A-chain residues with those from the INSL5 peptide
highlightedthattheN-terminusoftheA-chainofINSL3iscriticalforitsactivity.Remarkably,
replacement of the entire N-terminus with four or ﬁve alanine residues resulted in peptides
with near native activity suggesting that speciﬁc residues are not necessary for activity.
Additionally removal of two amino acids at the C-terminus of the A-chain and mutation of
Lys-8 in the B-chain also resulted in minor decreases in peptide activity.Therefore we have
demonstrated that the activity of the INSL3 peptide is driven predominantly by residues
5–9 in the A-chain, with minor additional contributions from the two C-terminal A-chain
residues and Lys-8 in the B-chain. Using this new knowledge, we were able to produce a
truncated INSL3 peptide structure which retained native activity, despite having 14 fewer
residues than the parent peptide.
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INTRODUCTION
Insulin-like peptide 3 (INSL3) was originally identiﬁed as a novel
gene highly expressed in the Leydig cells of the testis,and was ini-
tially named Leydig insulin-like peptide (Ley-I-L; Adham et al.,
1993).Itshomologytothepeptidehormonerelaxinalsoledtothe
name relaxin-like factor (RLF; Bullesbach and Schwabe, 1995).
However INSL3 is now its common name and it is known to be a
member of the relaxin peptide family. The relaxin peptides are all
characterized by a common structure comprising two chains (A
and B) that are cross-linked by disulﬁde bonds (Figure 1). This
arrangement results in a general structure in which three helical
segments (two in the A-chain and one in the B-chain) enclose a
hydrophobic core (Rosengren et al.,2009). Like other members of
this family, the native receptor for INSL3 is a G-protein coupled
receptor (GPCR; Hsu et al., 2002). INSL3 binds with high afﬁnity
to the leucine-rich repeat-containing, G protein coupled receptor
8 (LRG8; Kumagai et al., 2002), now known as the relaxin family
peptide receptor 2 (RXFP2; Bathgate et al.,2006a).
Insulin-like peptide 3 is expressed in the Leydig cells of every
mammalian species so far investigated (Bathgate et al., 2006b).
It is also expressed in the ovary (Ivell and Bathgate, 2002)w h e r e
it is localized in the follicular thecal cells and the corpus luteum
(Tashimaetal.,1995;Bathgateetal.,1996;Bambergeretal.,1999).
StudiesinINSL3(NefandParada,1999;Zimmermannetal.,1999)
andRXFP2(Gorlovetal.,2002)knockoutmalemicehavedemon-
strated that INSL3 acting through its receptor is essential for the
trans-abdominal phase of testicular descent where it is necessary
for the growth and development of the gubernaculum. Hence,
male mice lacking the INSL3 gene are bilaterally cryptorchid.
INSL3 is also a circulating hormone in adult males but its precise
roleisstillunknown.StudiesinratssuggestthatINSL3mayplaya
roleingermcellsurvivalinadultanimals(Kawamuraetal.,2004).
INSL3 treatment suppressed male germ cell apoptosis induced by
gonadotropin in male rats suggesting that INSL3 is a paracrine
factor involved in male germ cell survival. In the female a poten-
tial role for INSL3 in ovarian physiology was ﬁrst suggested by the
impairedfertilityfoundinfemaleINSL3knockoutmice(Nef and
Parada,1999).FurtherstudiesinanindependentINSL3knockout
mousestrain(Zimmermannetal.,1999)identiﬁedahigherappar-
ent rate of atresia or regression of both follicles and corpora lutea
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FIGURE 1 | Sequences and three dimensional structure of relaxin
peptides. (A) Sequences of the A- and B-chains of INSL3 and selected
related members of the relaxin peptide family. (B) Solution NMR structure of
INSL3 illustrating the typical overall fold of relaxins.The helical segments of
the A-chain are shown in cyan and the single helical segment of the B-chain is
shown in magenta.The conserved cysteine residues forming three disulﬁde
bonds are shown in ball-and-stick representation and are highlighted in yellow
in both panels and numbered sequentially by roman numbers.The disulﬁde
connectivity is illustrated by connecting lines in (A). Residues in the B-chain
that have been shown to be important for receptor binding are highlighted in
blue and additional residues whose potential roles in the activation of INSL3
are discussed throughout this paper are highlighted in green.
resulting in fewer follicles, corpora lutea, and offspring (Spanel-
Borowski et al., 2001). These data imply an important role for
INSL3 in protecting follicular and luteal cells from entering the
standard default pathway of apoptosis and atresia. Further evi-
dence for an anti-apoptotic role for INSL3 comes from studies
examining INSL3 expression in bovine follicles (Irving-Rodgers
et al., 2002). Studies in rats suggest that INSL3 may also have a
role in oocyte development (Kawamura et al., 2004). In vitro and
in vivo studies in cultured rat preovulatory follicles indicated that
INSL3 treatment initiates meiotic progression of arrested oocytes.
Hence the authors suggested that INSL3 may play a role in LH-
induced oocyte maturation. Importantly, all these studies suggest
that INSL3 has key roles in fertility in both males and females
andcompoundstargetingRXFP2maybenovelfertilityregulating
agents.
Human RXFP2 can be activated by both INSL3 and, at higher
concentrations, relaxin. However the native receptor for relaxin
is the closely related receptor RXFP1 (LGR7), for which INSL3
has a very poor afﬁnity. We now have a basic understanding of
the structural mechanisms by which relaxin and INSL3 bind to
and activate their receptors. The ligands bind to both the leucine
rich repeats (LRRs) of the receptor ectodomains and the trans-
membrane exoloops; the low density lipoprotein Class A (LDLa)
domainattheN-terminusof thereceptorisnecessaryforreceptor
activation (Hartley et al., 2009). Primary ligand binding occurs
between residues from the B-chain of the peptide and residues
in the inner beta-sheets of the LRRs of the receptor (Hartley
et al., 2009). These binding sites are well characterized for both
relaxin–RXFP1 (Bullesbach and Schwabe, 2005b) and INSL3–
RXFP2 (Scott et al., 2007). Current evidence suggests that relaxin
bindstotheRXFP2LRRsutilizingahybridrelaxin/INSL3binding
site comprising some of the INSL3–RXFP2 interactions but also
utilizingthepartiallyconservedRXFP1–relaxinbindingsiteinthe
RXFP2 LRRs (Scott et al., 2009). The peptide binding site in the
transmembraneexoloopsof thereceptorsislesswellcharacterized
but is believed to involve theA-chain of the peptides,although the
residues involved have not been fully determined in either the
peptides or the receptors. There is little known about the regions
of the relaxin A-chain involved in receptor interaction although
thereisconsiderableevidencetosuggestthattheN-terminusofthe
INSL3 A-chain is involved in the activation of RXFP2 by INSL3
(Bullesbach and Schwabe, 2005a, 2007). Importantly, unlike the
previously characterized INSL3 B-chain residues B12, B16, B19,
B20, and B27 which are involved in binding and activity (Bulles-
bach and Schwabe,2005a; Rosengren et al.,2006) the N-terminus
of the A-chain does not contribute to the binding afﬁnity. This
study set out to determine the key molecular determinants of the
INSL3 peptide involved in activation of the RXFP2 receptor.
MATERIALS AND METHODS
PEPTIDES
RecombinantDNA-derivedhumangene-2(H2)relaxinwaskindly
providedbyCorthera(SanMateo,CA,USA).Syntheticeuropium-
monolabeled INSL3 and native human INSL3 were prepared in-
houseaspreviouslydescribed(Rosengrenetal.,2006;Shabanpoor
et al.,2008).
SYNTHESIS OF INSL3 PEPTIDES
Each of the chimeric or mutant INSL3 peptides were prepared by
optimized solid phase synthesis of the separate A- and B-chains
followed by their combination via regioselective disulﬁde bond
formation as previously described (Zhang et al., 2010). Overall
yields of puriﬁed peptides averaged 10–14% based on starting
material in the form of cleaved B-chain and each was compre-
hensively chemically characterized by analytical RP-HPLC and
MALDI-TOF mass spectrometry. Amino acid analysis of acid
hydrolyzedaliquotsenabledpeptidequantitationpriortobioassay.
LIGAND BINDING ASSAYS
HEK-293T cells stably transfected with RXFP2 were seeded in
96 well Optiplates and Eu-INSL3 binding assays conducted as
described previously (Shabanpoor et al., 2008). Competition
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binding assays were performed using increasing concentrations of
unlabeled INSL3 and non-speciﬁc binding was determined using
1μM unlabeled INSL3. Data are expressed as mean±SEM of %
speciﬁc binding of triplicate measurements pooled from at least
three independent experiments. Data were analyzed using Graph-
Pad PRISM (GraphPad Inc) and a non-linear regression one-site
binding model was used to plot curves and calculate pKi val-
ues. Final pooled pKi data were analyzed using one-way ANOVA
coupled to Newman–Keuls multiple comparison test for multiple
group comparison.
cAMP ACTIVITY ASSAYS
The ability of the INSL3 peptide analogs to stimulate receptor
signaling was assessed using a cAMP reporter gene assay (Chen
et al., 1995) as previously described (Scott et al., 2006). Brieﬂy,
HEK-293T cells were co-transfected with receptor constructs and
apCRE–β-galactosidasereporterplasmid(Chenetal.,1995)in96
well plates. The RXFP2/1 construct contains the ectodomain of
RXFP2 fused to the transmembrane domains of RXFP1 and has
been previously described (Sudo et al., 2003; Halls et al., 2005).
Co-transfected cells were incubated with increasing concentra-
tions of INSL3 for 6h after which the media was aspirated and
the cells frozen at −80˚C overnight. The amount of cAMP-driven
β-galactosidase expression was then determined in each well as
described (Scott et al., 2006). The cAMP activity responses to
ligand stimulation were normalized to the maximal cAMP activ-
ity response to INSL3. Data points were performed in triplicate
and each experiment was repeated three times. Concentration
response curves were analyzed using GraphPad PRISM (Graph-
Pad Inc) and a sigmoidal dose–response curve with variable slope
model was used to plot curves and calculate pEC50 values. Final
pooled pEC50 data were analyzed using one-wayANOVA coupled
to Newman–Keuls multiple comparison test for multiple group
comparison.
RESULTS
CHIMERIC PEPTIDES
The INSL3 B-chain was combined with the A chains of other
relaxin family peptides to produce the chimeric peptides H2-
A/INSL3-B, INSL6-A/INSL3-B, and INSL5-A/INSL3-B (Table 1).
This strategy has been used previously to demonstrate the key
role of the relaxin A-chain in binding and activation of its recep-
tor RXFP1 (Liu et al., 2005). All of the chimeric peptides bound
to RXFP2 with high afﬁnity and similar pKi as INSL3 (Table 1,
Figure 2A). In contrast the ability of the chimeric peptides to
stimulate cAMP activity in RXFP2 receptor expressing cells was
severely compromised. INSL6-A/INSL3-B and INSL5-A/INSL3-B
were unable to stimulate cAMP in concentrations up to 1μM.
These chimeric peptides therefore must be able to bind to RXFP2
with high afﬁnity through the INSL3 B-chain but have lost the
ability to activate RXFP2 and are high afﬁnity antagonists.
The H2-A/INSL3-B chimera was expected to be able to bind
and activate RXFP2 as H2 relaxin is also a full agonist of RXFP2
(Table 1, Figure 2B). However, while H2-A/INSL3-B was able to
bind to RXFP2 with high afﬁnity, and it showed a similar pEC50
to both INSL3 and H2 relaxin it was only able to stimulate to
45% of the maximal INSL3 effect demonstrating properties of a
partial agonist (Table 1,Figure2B).We postulated that this prob-
ably reﬂects the fact that native H2 relaxin binds and activates
RXFP2 in a different manner to INSL3. Thus the binding of the
INSL3 B-chain to the RXFP2 LRRs may not be compatible with
thebindingmodeoftheH2relaxinA-chaintothetransmembrane
domain of RXFP2. To test this hypothesis,we examined the activ-
ity of H2-A/INSL3-B chimera on a chimeric receptor RXFP2/1,
wherebytheectodomainof RXFP2isfusedtothetransmembrane
domains of RXFP1. As demonstrated in Figure 3, H2-A/INSL3-B
appears to behave, like INSL3 and H2 relaxin, as a full agonist at
this chimeric receptor, i.e., the RXFP1 transmembrane domains
are able to rescue the full agonist activity of this peptide.
INSL5-A/INSL3-B PARTIAL CHIMERAS
The chimeric peptide experiments above indicated that the A-
chain of INSL3 is responsible for the ability of INSL3 to activate
RXFP2. Therefore as a means to determine the A-chain region(s)
thatmediatetheactivationbyINSL3,wepreparedINSL3peptides
in which INSL3 A-chain residues were replaced with those from
the INSL5 peptide as the INSL5-A/INSL3-B peptide was com-
pletely inactive (Table 1). Importantly, all of the partial chimeras
were able to bind to RXFP2 with near native afﬁnity (Table 1,
Figure 4A). Replacement of residues within the core of the A-
chain from amino acid 12–23 to INSL5 speciﬁc residues had no
effectontheactivityof thechimericpeptideswhichindicatedthat
residues in this region are not involved with receptor activation
(Table 1, Figure 4B). In contrast, replacement of residues 1–9
with the six residues of the INSL5A-chain N-terminus resulted in
a signiﬁcant loss of peptide activity. We then replaced individual
regions of the A-chain N-terminus A5/6 and A8/9 but neither of
these substitutions resulted in a loss of peptide activity.
INSL3 A-CHAIN VARIANTS
The ﬁnding that replacement of the entire N-terminal portion of
INSL3, residues A1–9, with the N-terminal portion of INSL5 sig-
niﬁcantly affected activation, but that no effects were seen when
smallersegmentswerechangedisintriguing.Itishoweverinagree-
ment with previous data showing that individual replacement of
residuesinthisregionwithalaninesdoesnothaveanaffectonsig-
naling (Bullesbach and Schwabe,2005a). To further investigate we
replaced the entire region with either four or ﬁve consecutive ala-
nine residues to createAla-4A(10–26) INSL3 andAla-5A(10–26)
INSL3. Both of these peptides bound to RXFP2 with near native
afﬁnity (Table 2,Figure5A) and,in contrast to the variants carry-
ing the INSL5 N-terminal portion of the A-chain, were also able
to act as full agonists albeit with slightly lower potency than the
native peptide (p <0.05 compared to INSL3,Table 2, Figure 5B).
Therefore it is clear that the actual residues in these positions are
not important for the ability of INSL3 to activate its receptor.
Additionally,we investigated the role of the two residues at the
A-chain C-terminus. INSL3 peptides from all species contain two
amino acids in this position (Wilkinson et al.,2005) but the effect
ofremovaloftheseresiduesonpeptideactivityhasnotbeentested.
Although INSL3 Δ25/26 demonstrated binding afﬁnity compara-
tive to that of INSL3 (Table 2, Figure 6A), it showed signiﬁcantly
reduced ability to stimulate cAMP compared to the native peptide
(p <0.01, Table 2, Figure 6B). The A-chain C-terminus therefore
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Table 1 | Sequences and receptor binding afﬁnities (pKi) and receptor activation (pEC50) activities of INSL3, H2 relaxin, and INSL3 chimeric
peptides.
Peptide Sequence Receptor binding Receptor activation
pKi (n=) pEC50 (n=)
INSL3 9.22±0.07 (6) 10.34±0.06 (7)
H2 relaxin 7 .91±0.06*** (3) 9.13±0.06 (3)*
CHIMERIC PEPTIDES
H2-A/INSL3-B 8.52±0.14 (3) 9.55±0.14 (3)
Emax=45.2±1.8%
INSL6-A/INSL3-B 8.50±0.14 (3) No activity (3)
INSL5-A/INSL3-B 9.15±0.22 (3) No activity (3)
INSL3 (A12/13 INSL5) 8.69±0.14 (3) 10.21±0.16 (5)
INSL3 (A16–23 INSL5) 9.21±0.14 (3) 10.13±0.05 (3)
INSL3-B (1–6 INSL5/10–26 INSL3)-A 8.44±0.12 (3) 8.42±0.43 (3)***
INSL3 (A8/9 INSL5) 9.04±0.08 (3) 10.31±0.24 (5)
INSL3 (A5/6 INSL5) 9.02±0.18 (3) 9.93±0.06 (4)
*p<0.05, ***p<0.001 vs. INSL3. Shaded amino acids are those which have been changed to INSL5 residues in the chimeric peptides.
appears to play at least a small role in the ability of INSL3 to
activate its receptor.
INSL3 B-CHAIN VARIANTS
PreviousstudieshavealsosuggestedthatspeciﬁcresiduesintheB-
chain N-terminus may also contribute to the activity of the INSL3
peptide(BullesbachandSchwabe,2007).Toconﬁrmtheseﬁndings
we synthesized two INSL3 B-chain mutants to assess their activ-
ity in our cell systems. GluB7 to alanine did not show any affect
on either binding or activation, consistent with previous ﬁndings
(Bullesbach and Schwabe,2006). However,contrary to a previous
report (Bullesbach and Schwabe, 2006) mutation of LysB8 to ala-
nine did result in the loss of peptide activity (p <0.05) without
any effect on receptor binding (Table 3,Figures6A,B). This result
is not likely to be due to differences in cell line or signaling assay
used as the authors also measured cAMP signaling in transfected
HEK-293T cells (Bullesbach and Schwabe, 2006). It is therefore
possible that this residue does play a role in receptor activation.
TRUNCATED INSL3 ANALOGS
Finally based on the knowledge of the role of speciﬁc residues
in the A-chain and B-chain of INSL3 that are important for
binding and activity, we postulated truncated INSL3 analogs that
would retain most of the native activity. We therefore synthesized
INSL3 A(5–26)/B(1–27) and tested its ability to bind and activate
RXFP2. This peptide retained high afﬁnity binding and was able
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FIGURE 2 |Activity of the INSL3 chimeric peptides on the RXFP2
receptor. (A) Competition binding utilizing Eu-labeled INSL3 compared to
INSL3 and H2 relaxin. Data are expressed as the percentage of speciﬁc
binding and are pooled from at least three experiments with triplicate
determinations within each assay. (B) cAMP activity compared to INSL3
and H2 relaxin measured utilizing a pCRE–β-galactosidase reporter gene
assay. Data are expressed as the percentage INSL3 maximum activity and
are pooled data from at least three experiments with triplicate
determinations within each assay.
FIGURE 3 | cAMP activity of H2-A/INSL3-B compared to INSL3 and H2
relaxin at the RXFP2/1 chimeric receptor measured utilizing a
pCRE–β-galactosidase reporter gene assay. Data are expressed as the
percentage INSL3 maximum activity and are pooled data from at least
three experiments with triplicate determinations within each assay.
to activate cAMP with only slightly reduced potency compared to
native INSL3 (Table 3, Figures 7A,B). We therefore synthesized
INSL3 A(5–26)/B(7–27) which was also demonstrated to retain
high afﬁnity binding and also retained similar potency compared
to native INSL3 (Table 3, Figures 7A,B). We have therefore been
able to produce a truncated INSL3 peptide that possesses 14 fewer
FIGURE 4 |Activity of the INSL5-A/INSL3-B partial chimeric peptides
on the RXFP2 receptor. (A) Competition binding utilizing Eu-labeled INSL3
compared to INSL3 and H2 relaxin. Data are expressed as the percentage
of speciﬁc binding and are pooled from at least three experiments with
triplicate determinations within each assay. (B) cAMP activity compared to
INSL3 and H2 relaxin measured utilizing a pCRE–β-galactosidase reporter
gene assay. Data are expressed as the percentage INSL3 maximum activity
and are pooled data from at least three experiments with triplicate
determinations within each assay.
residues than the native peptide,i.e.,25% smaller and retains near
native activity.
DISCUSSION
Thebindingof ligandtoRXFP1andRXFP2andsubsequentstruc-
tural rearrangements that lead to intracellular signaling through
these receptors is a complex process (Bathgate et al., 2006a; Scott
et al., 2006). Although the signiﬁcant efforts directed at under-
standing the ligand mediated activation of these receptors over
recent years have led to a number of new insights, in particular a
detailed picture of the interaction between the hormone B-chain
and the receptor LRR domain,still very little is known about how
thereceptorsareactivated.Thisstudywasdesignedtoshedfurther
light on the activation of RXFP2 by INSL3.
INSL3 CHIMERAS CONFIRM THE ROLE OF THE INSL3 A-CHAIN IN
RECEPTOR ACTIVATION
Given the two-chain nature of the relaxin peptides creation of
chimeric ligands comprising an A- and a B-chain from different
relaxins offers a convenient way to decipher the role of differ-
ent domains in binding and activation of the relaxin receptors.
Chimeric variants of the related relaxin-3 peptide were instru-
mental in decoding the key role of the A-chain in the ability of
relaxin-3 to activate RXFP1, while also showing that the A-chain
is not necessary for activation of its endogenous receptor RXFP3
(Liu et al., 2005). This observation led to the subsequent design
of peptides that selectively target RXFP3 (Liu et al., 2005; Kuei
et al., 2007; Haugaard-Kedstrom et al., 2011). Structural studies
usingNMRspectroscopyrevealedminimaloverallstructuraleffect
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Table 2 | Sequences and receptor binding afﬁnities (pKi) and receptor activation (pEC50) activities of INSL3 and INSL3A chain variants.
Peptide Sequence Receptor binding Receptor activation
pKi (n=) pEC50 (n=)
INSL3 9.22±0.07 (6) 10.34±0.06 (7)
INSL3A CHAINVARIANTS
INSL3 ΔA25/26 8.59±0.06 (3) 9.07±0.16 (3)**
Ala-5 A(10–26) INSL3 8.80±0.13 (3) 9.51±0.08 (3)*
Ala-4 A(10–26) INSL3 8.88±0.10 (3) 9.19±0.28 (3)*
*p<0.05, **p<0.01 vs. INSL3. Shaded area is the alanine residues that have been added to the truncated INSL3 peptide.
FIGURE 5 |Activity of INSL3A-chain variant peptides on the RXFP2
receptor. (A) Competition binding utilizing Eu-labeled INSL3 compared to
INSL3 and H2 relaxin. Data are expressed as the percentage of speciﬁc
binding and are pooled from at least three experiments with triplicate
determinations within each assay. (B) cAMP activity compared to INSL3
and H2 relaxin measured utilizing a pCRE–β-galactosidase reporter gene
assay. Data are expressed as the percentage INSL3 maximum activity and
are pooled data from at least three experiments with triplicate
determinations within each assay.
when combining the relaxin-3 B-chain with the INSL5 A-chain,
suggesting that relaxin chains are generally interchangeable with-
out large conformational effects (Haugaard-Jonsson et al., 2008).
Here we generated a series of chimeric peptides based on the
INSL3 B-chain, which is known to carry the primary receptor
FIGURE 6 |Activity of INSL3 B-chain variant peptides on the RXFP2
receptor. (A) Competition binding utilizing Eu-labeled INSL3 compared to
INSL3 and H2 relaxin. Data are expressed as the percentage of speciﬁc
binding and are pooled from at least three experiments with triplicate
determinations within each assay. (B) cAMP activity compared to INSL3
and H2 relaxin measured utilizing a pCRE–β-galactosidase reporter gene
assay. Data are expressed as the percentage INSL3 maximum activity and
are pooled data from at least three experiments with triplicate
determinations within each assay.
binding site directed toward the RXFP2 LRRs (Bullesbach and
Schwabe,2006;Rosengrenetal.,2006;Scottetal.,2007).Strikingly
all chimeric peptides displayed negligible change of RXFP2
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Table 3 | Sequences and receptor binding afﬁnities (pKi) and receptor activation (pEC50) activities of INSL3, INSL3 B chain variants, and
truncated INSL3 analogs.
Peptide Sequence Receptor binding Receptor activation
pKi (n=) pEC50 (n=)
INSL3 9.22±0.07 (6) 10.34±0.06 (7)
INSL3 B CHAINVARIANTS
INSL3 B(K8A) 9.21±0.11 (3) 9.41±0.16* (4)
INSL3 B(E7A) 9.06±0.21 (3) 10.23±0.27 (3)
TRUNCATED INSL3
INSL3 A(5–26)/B(1–27) 8.51±0.02 (3) 9.73±0.26 (3)
INSL3 A(5–26)/B(7–27) 8.79±0.15 (3) 9.99±0.08 (3)
*p<0.05 vs. INSL3.The shading highlights the amino acid which has been changed to alanine in the mutant peptides INSL3 B(K8A) and B(E7A).
binding but analogs carryingA-chains from INSL5 or INSL6 were
unable to induce any receptor signaling, highlighting the role of
the INSL3 A-chain in the activation of RXFP2. In contrast, when
the H2 relaxin A-chain was combined with the INSL3 B-chain, a
moleculewasobtainedthatactivatedRXFP2withanEC50similar
to native INSL3. However, this compound has an Emax of only
45% revealing that this peptide is only a partial agonist. This ﬁnd-
ing is particularly interesting given that H2 relaxin itself is a full
agonist for RXFP2.
We postulated that this was probably due to H2 relaxin bind-
ing and activating RXFP2 in a different manner to INSL3. Hence
the mode by which the INSL3 B-chain binds to the RXFP2 LRR
domain is not fully compatible with the interaction between the
H2 relaxin A-chain and the RXFP2 extracellular loops necessary
forfullreceptoractivation.Toconﬁrmthisidea,thechimericpep-
tide was tested against a chimeric receptor comprising the LRR
domain of RXFP2 attached to the transmembrane domain of the
H2 relaxin receptor RXFP1 (Sudo et al., 2003). In this system full
activationofthereceptorwasobserved,clearlydemonstratingthat
despite the structural similarities of both H2 relaxin/INSL3 and
their receptors RXFP1/RXFP2 the mechanism whereby the pep-
tides activate their receptors is distinctly different. Importantly
the mechanism of activation appears to be guided by the peptide
rather than the receptor,i.e.,H2 relaxin activates RXFP2 in a sim-
ilar way as it actives RXFP1 rather than the way INSL3 activates
RXFP2.Thisisconsistentwithpreviousdatashowingthattrunca-
tion of the H2 relaxinA-chain had differing effects on the binding
and activation of RXFP1 and RXFP2 (Hossain et al., 2008).
To further narrow down the regions of importance in the
INSL3 A-chain a series of partial A-chain chimeras of INSL3 and
INSL5 were created. Although introduction of residues from the
A-chain of INSL5 in the region 12–23 had little or no effect on
the potency of the peptide, replacement of residues A1–9 with
residuesA1–6of INSL5resultedinasigniﬁcantdecreaseinactiva-
tionof RXFP2.Thisﬁndingisconsistentwithprevioustruncation
studies demonstrating that residues A1–5 of INSL3 can be trun-
cated without detrimental effect,but that further truncations lead
to a decrease in receptor activation; indeed, a peptide lacking
the ﬁrst eight residues is a high afﬁnity antagonist (Bullesbach
and Schwabe, 2005a, 2007). It is interesting that the introduction
of only two residues from INSL5 at a time (i.e., A5/6 or A8/9),
had no effect on receptor activation. This was consistent with
previous studies which demonstrated that mutations of A8/9 to
alanine had no effect on INSL3 activity (Bullesbach and Schwabe,
2006).
ALANINE SUBSTITUTIONS REVEAL THAT NO INDIVIDUAL RESIDUES IN
THE A-CHAIN ARE CRITICAL FOR ACTIVITY
In light of our ﬁndings that replacement of the entire N-terminal
region but not smaller segments affected receptor activation, and
the previously published data in which replacement of individual
residues with alanines were found not to compromise activation
(Bullesbach and Schwabe,2006),we created two analogs compris-
ingstringsofalaninesprecedingCysA10.Thisregionadoptsahelix
in native INSL3;one would expect that the added alanine residues
would be able to retain the native structure, but they would do so
without presenting any functionally relevant side chains. Indeed
bothAla5-andAla4-(A10–26)INSL3wereabletoactivateRXFP2,
indicatingthatan“inert”peptidebackboneinthisregionofINSL3
is sufﬁcient for receptor activation.
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FIGURE 7 |Activity of INSL3 truncated peptides on the RXFP2 receptor.
(A) Competition binding utilizing Eu-labeled INSL3 compared to INSL3 and
H2 relaxin. Data are expressed as the percentage of speciﬁc binding and are
pooled from at least three experiments with triplicate determinations within
each assay. (B) cAMP activity compared to INSL3 and H2 relaxin measured
utilizing a pCRE–β-galactosidase reporter gene assay. Data are expressed
as the percentage INSL3 maximum activity and are pooled data from at
least three experiments with triplicate determinations within each assay.
WHAT IS THE MECHANISM OF ACTIVATION OF RXFP2 BY INSL3?
Our data and previous studies ﬁrmly establish the region of
residuesA6–A9inINSL3asthekeydomainforreceptoractivation
(Bullesbach and Schwabe,2005a,2006,2007). However,it is strik-
ing that neither previous studies nor our work here have been
able to identify any signiﬁcant contributions from the individual
side chains present in this region. In fact replacing the entire N-
terminalsegmentwithaseriesofalaninesissufﬁcientforretaining
receptor activation. It has been suggested that rather than contri-
butions from side chain groups the key drivers of the interaction
may be hydrogen bonding interactions involving the polar groups
of the peptide backbone (Bullesbach and Schwabe, 2007). Based
on the multi-alanine versions presented here this appears to be
the only logical explanation, but if the nature of the residues
in this region is irrelevant, why is the peptide carrying the N-
terminal portion of the INSL5 A-chain unable to fully activate
the receptor? The answer may be that a particular structure in
this region is required for the correct orientation of the backbone
groups for the interaction with the receptor. The NMR solution
structure of native INSL3 reveals that the N-terminal region, like
insulin and other relaxin peptides, adopts a helical conformation.
In INSL3 the helical region spans residues A6–A12, while the N-
terminal ﬁve residues are disordered (Rosengren et al., 2006).
Should this structure be retained upon receptor binding then
the amide protons of AlaA7 and ArgA8, which are not involved
in inter-helical hydrogen bonds and constitute the positive part
of the helix dipole would be prime candidates for interacting
with the receptor. Bullesbach and Schwabe (2007) showed that
N-methylatingArgA8orTyrA9andtherebyremovingtheirhydro-
gen bonding ability attenuates receptor activation, which would
be consistent with such an interaction. In the NMR structure of
INSL5 the A-chain N-terminal helix extends further towards the
N-terminus, likely because the N-terminal residue is a pyroglu-
tamic acid removing the clash between the N-terminal positive
charge and the helix dipole; the helix is further stabilized by the
presence of an Asp at position A2, which caps the N-terminal
part of the helix (Haugaard-Jonsson et al., 2009). These features
may explain the inability of the INSL5 A-chain to activate RXFP2
in the chimeric peptides. We cannot of course rule out the pos-
sibility that it is a requirement for activation that the structure
in this region is altered upon binding to RXFP2, and that by
introducing a more stable helix, this structural rearrangement is
prevented. Such an event could expose further hydrogen bond
donors and acceptors of the peptide backbone for interaction
with the receptor. The N-terminal region of INSL3 is somewhat
dynamic as evident from amide exchange rates and line broad-
ening observed in NMR studies, and this dynamic character may
be relevant for function (Rosengren et al., 2006), but the nature
of what an altered receptor bound form might be is difﬁcult to
predict.
DO OTHER REGIONS OF INSL3 CONTRIBUTE TO THE ACTIVATION
DOMAIN?
Bullesbach and Schwabe (2005a, 2007) demonstrated that trun-
cation of up to ﬁve residues of the B-chain N-terminus does not
affect binding or signaling, but that further truncations result in
a step wise decrease in both binding and activation. Again this
contribution was speculated to be independent of the nature of
the side chains in this region, as replacement of either GluB7 or
LysB8 with alanine did not appear to affect receptor binding or
activation. We decided to revisit these ﬁndings and synthesized
thesetwoanalogs.ConsistentwithpreviousdatatheGluB7toala-
nine analog showed native-like binding and activation. However,
in contrast to the previous report we found that the substitution
in INSL3 of LysB8 with alanine caused a signiﬁcant drop in acti-
vationof RXFP2withnochangeinbindingafﬁnity.Hence,unlike
substitution of other B-chain residues where loss of activity is
associated with loss of binding, LysB8 appears to be involved in
activation only. An analysis of the INSL3 NMR structure reveals
that LysB8 is tightly associated with the C-terminal part of the
A-chain N-terminal helix, providing a capping effect by inter-
acting with the carbonyls of CysA11, LeuA12, and SerA13. This
interaction with the negative part of the helix dipole is likely
to have a signiﬁcant stabilizing effect on the helix and thus the
effects of severely truncating or mutating the B-chain N-terminal
region on RXFP2 receptor activation may be related to a sec-
ondary structural effect destabilizing the A-chain, rather than
direct contacts with the receptor. Here we also demonstrated
that truncation of the C-terminal two residues of the INSL3 A-
chain decreased activity. These residues are rather distant from
the key N-terminal region of the A-chain and it would seem
unlikely that they form part of the same receptor interaction
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responsible for activation. More likely is that this observation is
related to disruption of contacts between the two A-chain helices
or to interference with the spatial coordination of the activa-
tion domain in the A-chain with the key LRR primary binding
site in the B-chain, which is in close contact with ProA25 and
TyrA26.
MINIMAL ACTIVE STRUCTURE OF INSL3
Finally, utilizing the data gained in this study, and from previ-
ous studies, we designed INSL3 peptides that should represent
active truncated INSL3 analogs. We were able to show that INSL3
A(5–26)/B(7–27)retainednearnativeactivity.Thispeptideis25%
smallerthanthenativepeptideandthuseasierandcheapertomake
andrepresentsapotentialleadpeptideforfurtherdevelopmentof
smaller INSL3 analogs that may have great therapeutic potential
as fertility regulators.
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